about
Identification and functional analysis of a new phosphorylation site (Y398) in the SH3 domain of Abi-1A new view of carcinogenesis and an alternative approach to cancer therapySpatial Genome Organization and Its Emerging Role as a Potential Diagnosis ToolEfficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature ReviewMolecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and OutcomesA systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemiaUtilization of genomic signatures to identify phenotype-specific drugsImatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemiaAssay development and high-throughput screening of small molecular c-Abl kinase activators.RNA quantification using gold nanoprobes - application to cancer diagnosticsAltered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia.Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.Identification of heptapeptides interacting with IFN-α-sensitive CML cells.Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor gliomaDysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesThe European LeukemiaNet: achievements and perspectives.Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.The role of funding and policies on innovation in cancer drug development.Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemiaGPX3 promoter is methylated in chronic myeloid leukemia.Clinical cardiac safety profile of nilotinib.Comparison of the utility and applicability of the Sokal, Hasford, and EUTOS scores in a population of Chinese patients with chronic-phase chronic myeloid leukemia undergoing imatinib therapyIschemic colitis during interferon-ribavirin therapy for chronic hepatitis C: a case report.Relationship between cigarette smoking and risk of chronic myeloid leukaemia: a meta-analysis of epidemiological studies.Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatmentThe impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in Chronic Myeloid Leukaemia.Blocking p55PIK signaling inhibits proliferation and induces differentiation of leukemia cells.Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitorsA multicellular basis for the origination of blast crisis in chronic myeloid leukemiaThe pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemiaEvaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care.A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
P2860
Q24293171-445CDF57-8891-4E9B-9802-2725732F7AEDQ24650249-E1E453D8-A6AA-4538-B0E9-791D35F00C93Q26738275-2C8DFA28-BEF3-4A91-A0DC-A84F22EC5742Q26775622-0D26526A-F24D-4AB8-B483-09DB8CA1A192Q27853066-C37CBE8C-23D5-4B78-9BD4-81B308BF2113Q28081319-FD15F754-5CC6-4A3A-8A65-5B4E2533C440Q28387697-9CA3D90F-08D7-4421-B379-6AFD35C933B5Q28476014-DD9153DF-090F-4C3D-8C7B-81448D9442C8Q28477798-71B215D5-F16F-400A-A06B-BB1EF0BCAA9EQ33715301-C1051EE8-5E6F-49D0-BCD7-A0FED834CCACQ33748792-543CE0AA-2D2E-4D4F-B8DF-9646F4E81D50Q33862129-312B365C-83BA-4169-A8FF-D0B656D7D40AQ33926114-21AE418B-C83F-4248-AB57-A86285516A84Q34076524-C03F5AAF-B64E-4146-90B5-80EB91B65CA0Q34083282-23213F6E-6EE4-4AEB-8E85-EEC44245DBBFQ34139691-663D57CE-4F29-4044-A50C-8A67E18EA75DQ34451619-3C5CA806-C9BD-4981-80A3-D0621C509D07Q34642865-1236D823-5205-48C4-A726-3D1118547EFCQ35602147-F2C7A7B0-E357-43A0-9ED7-0CE5DACC2E8CQ35633858-D8FD28EC-3167-484B-AFDC-E86F582BF1FFQ35852817-3B806D55-EC76-4DB6-9E41-CE166CC22C08Q35919012-06F15A58-FC6D-4F7F-82BF-523A54A22CFAQ36006389-058F800D-D13F-43B0-AEB9-5151AE229DA5Q36068354-5BB3A1E5-78B3-480E-BF1B-29A9E3A06B79Q36175105-76114CA3-57B2-4E1B-9A2D-29F5523F5E36Q36180564-07FF4CF3-9ED2-4F0B-8DD1-EFF1D8A469E1Q36288815-12E3D36D-337B-4780-9DAD-C9833FF591E7Q36309977-E9C3A2DF-DF55-484E-A082-55C4AC37B6F1Q36311164-34BE3566-AD04-4D8A-8656-F680250CD7D8Q36364835-39B8AB2D-50C4-48E6-9BB6-6947130FB272Q36509949-0CA825EC-FEB3-4B5F-8D75-75436C455424Q36510458-175C8C74-A44E-42EC-A7CC-AB5224BD6BB0Q36804884-29EAC687-DD83-4F49-BBCB-64140E418760Q36857570-7F744990-FFD9-4A86-8E18-4B4E018714DFQ37000538-43F4C67F-11CE-4F2D-9D2D-FE0856B6ACCFQ37026032-2BB413AB-1085-40CB-85E2-2B80C000F900Q37148391-B43989EF-708F-4687-8E2A-C6BC6E00BEA1Q37163550-79D145CE-AFAB-4CF8-83F0-3330EF9AEFFBQ37234005-3107A9B8-AEC1-4167-BF37-8F0E5D53D9F4Q37334945-8F72166B-5232-4BD8-9837-7746D558DB54
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Chronic myeloid leukaemia.
@ast
Chronic myeloid leukaemia.
@en
Chronic myeloid leukaemia.
@nl
type
label
Chronic myeloid leukaemia.
@ast
Chronic myeloid leukaemia.
@en
Chronic myeloid leukaemia.
@nl
prefLabel
Chronic myeloid leukaemia.
@ast
Chronic myeloid leukaemia.
@en
Chronic myeloid leukaemia.
@nl
P1433
P1476
Chronic myeloid leukaemia.
@en
P2093
European LeukemiaNet
Rüdiger Hehlmann
P304
P356
10.1016/S0140-6736(07)61165-9
P407
P577
2007-07-01T00:00:00Z